SEC Comment Letter for ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — Jun 22, 2017
ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: June 22, 2017 · CIK: 0001368514 · Accession: 0000000000-17-021903
AI Filing Summary & Sentiment
Reasoning
Letter
June 21, 2017 Adam S. Grossman Chief Executive Officer ADMA Biologics, Inc. 465 State Route 17 Ramsey, NJ 07446 ADMA Biologics, Inc. Registration Statement on Form S-3 Filed June 16, 2017 File No. 333-218802Re: Dear Mr. Grossman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at (202) 551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: David C. Schwartz, Esq.
Show Raw Text
June 21, 2017
Adam S. Grossman
Chief Executive Officer
ADMA Biologics, Inc.
465 State Route 17
Ramsey, NJ 07446
ADMA Biologics, Inc.
Registration Statement on Form S-3
Filed June 16, 2017
File No. 333-218802Re:
Dear Mr. Grossman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at (202) 551-3798 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: David C. Schwartz, Esq.